ArticleFrontiers in oncology2025
Primary breast diffuse large B-cell lymphoma (germinal center B-cell-like subtype): a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary breast diffuse large B-cell lymphoma mimicking breast carcinoma: a case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary breast lymphoma (PBL) is a rare type of extranodal lymphoma, of which diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype. Due to its nonspecific clinical and imaging features, PBL is frequently misdiagnosed as breast carcinoma or mastitis, leading to delays in treatment. Case Presentation: We report the case of a postmenopausal female who presented with a rapidly enlarging mass in the left breast and was initially misdiagnosed as non-lactational mastitis. Core needle biopsy and immunohistochemistry revealed features consistent with DLBCL of the germinal center B-cell-like (GCB) subtype. Notably, the tumor cells co-expressed Bcl-2 (95%) and c-Myc (70%), meeting the criteria for double expressor lymphoma (DEL), suggesting aggressive biological behavior. Serum lactate dehydrogenase (LDH) was markedly elevated (3902 U/L), indicating high tumor burden. Despite palliative surgery, the patient's condition rapidly deteriorated. Discussion: GCB-type DLBCL generally carries a better prognosis than the activated B-cell-like (ABC) subtype; however, significant heterogeneity exists within the GCB subtype. DEL is recognized as a high-risk variant associated with poor outcomes, regardless of cell of origin. This case emphasizes the diagnostic challenges of PBL and highlights the need for precise immunophenotyping and individualized therapy. LDH elevation may reflect hypoxia-induced metabolic reprogramming and potential treatment resistance via the HIF-1α pathway. Conclusion: Accurate diagnosis of primary breast DLBCL requires careful differential evaluation. Immunohistochemical profiling and LDH monitoring are crucial for prognostic assessment and treatment planning. More clinical data are needed to optimize management strategies for this rare entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.